Heart Disease News and Research

Latest Heart Disease News and Research

Researchers develop hybrid tissue-engineered heart valve using patient's own cells

Researchers have created a new heart valve that combines a patient's own cells with metal alloy for a more durable replacement with potentially fewer complications, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.

2 Jun 2015

CHLA opens doors of new Encino outpatient care center

Children's Hospital Los Angeles opened the doors of its new outpatient care center in Encino today. The pediatric medical facility, Children's Hospital Los Angeles - Encino, will be staffed by physicians who are Board-certified in pediatric specialties and subspecialties, including hematology-oncology, nephrology, neurology, orthopaedics, pediatric surgery and urology.

2 Jun 2015

Surgical resection, chemo and radiation therapy combination could benefit metastatic NSCLC patients

Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.

2 Jun 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.

2 Jun 2015

Groundbreaking, combination vaccine may help beat Streptococcus A infections

Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.

2 Jun 2015

Invitae introduces new patient pay program to make genetic testing more affordable, accessible

Invitae Corporation, a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication.

2 Jun 2015

Pivotal Therapeutics reports net loss of $1.2 million for first quarter 2015

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2015.

2 Jun 2015

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

The National Psoriasis Foundation received a second-year of funding from the Patient-Centered Outcomes Research Institute (PCORI) for its patient-driven, online research community.

1 Jun 2015

Importance of nut consumption impressed on International Children's Day

According to the World Health Organization (WHO), excess weight and obesity are two of the most serious public health challenges of the 21st century.

1 Jun 2015

Key lifestyle changes could help reduce risk of cognitive decline

The evidence is mounting: People can reduce their risk of cognitive decline by making key lifestyle changes. That is the conclusion of a new research summary published online today in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

1 Jun 2015

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

For many people, bug bites and bee stings aren't a big deal beyond a small irritation. But for some, it could mean the start of a painful - possibly long-term or even deadly - experience.

1 Jun 2015

Heart-healthy diet may benefit men after prostate cancer diagnosis

After a prostate cancer diagnosis, eating a diet higher in red and processed meat, high-fat dairy foods, and refined grains--known as a Western diet--may lead to a significantly higher risk of both prostate cancer-related mortality and overall mortality compared with eating a diet rich in vegetables, fruits, fish, whole grains, and healthy oils, according to a new study from Harvard T.H. Chan School of Public Health.

1 Jun 2015

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Resverlogix Corp. today announced that new data on RVX-208 was presented at the ERA-EDTA Congress in London, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects with a History of CVD, and Chronic Kidney Disease (CKD); a Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ASSURE Clinical Trials."

1 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Premature mortality target highly unethical and explicitly ageist

One of the main health targets proposed by the UN Sustainable Development Goals (SDG) is to reduce by one-third premature mortality from non-communicable diseases such as cancer, stroke and dementia. The goals for 2016-2030 define premature mortality as deaths occurring among people aged 69 years old or younger.

1 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Heart Disease News and Research

Latest Heart Disease News and Research

Researchers develop hybrid tissue-engineered heart valve using patient's own cells

CHLA opens doors of new Encino outpatient care center

Surgical resection, chemo and radiation therapy combination could benefit metastatic NSCLC patients

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Groundbreaking, combination vaccine may help beat Streptococcus A infections

Invitae introduces new patient pay program to make genetic testing more affordable, accessible

Pivotal Therapeutics reports net loss of $1.2 million for first quarter 2015

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

Importance of nut consumption impressed on International Children's Day

Key lifestyle changes could help reduce risk of cognitive decline

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

Heart-healthy diet may benefit men after prostate cancer diagnosis

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Premature mortality target highly unethical and explicitly ageist

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Heart Disease News and Research

Latest Heart Disease News and Research

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in